Imagine a weight-loss drug that not only helps you shed a few pounds, but does so without asking you to diet or exercise. In an industry dogged by safety concerns, a private U.S. company is betting on a new approach to deliver just such a treatment that could end up being the first billion-dollar diet drug. Initial trials show that Zafgen Inc, run by a former Novartis AG executive, might have an edge over its competitors, especially since its experimental drug has so far not demonstrated any major safety concerns.
Help employers find you! Check out all the jobs and post your resume.
